Aims and Scope Pain and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pain therapies and ...
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulat
Gene therapy is at an inflection point. Recent successes in genetic medicine have paved the path for a broader second wave of therapies and laid the foundation for next-generation technologies. This comment summarizes recent advances and expectations for the near future. The past five years have s...
Deferoxamine mesylate, first introduced in short-term studies in iron-loaded patients in the early 1960s, gained acceptance as standard therapy over a decade later in countries able to support the high costs of this therapy. Twenty years later, extended survival free of iron-induced complications,...
This Practice Point discusses the 10-year data of the RTOG 8610 trial, published by Roach III and colleagues, which suggest that a short, 4-month course of neoadjuvant-concomitant deprivation therapy () might be sufficient to improve clinically relevant long-term outcomes in men with bulky, loca...
Today, it is certain that tumour-specific T-cells can be found in high numbers among tumour-infiltrating lymphocytes (TIL) (Romero et al, 1998), but this T-cell response usually does not translate into healing progress. Tumour antigen reactivity usually is weak, these T cells are naturally ...
high-dose trastuzumab maintenance therapy 10 mg/kg every 3 weeks until progression. Results showed that the high-dose regimen was associated with increased trastuzumab levels of concentration but did not result in improved OS. The exploratory analyses indicate patients with higher HER2 levels (IHC 2...
Mantis Low Volume Chip Fisher Scientific Cat# NC1491372 Mantis High Volume Chip Fisher Scientific Cat# NC1491373 RNeasy Mini Kit QIAGEN Cat# 74104 Bioanalyzer RNA 6000 Pico kit Agilent Cat# 5067-1514 Qubit RNA HS Assay kit Thermo Fisher Scientific Cat# Q32852 First Strand Synthesis Kit QIAGEN ...
Sarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute, Durham, NC, USA Alec G. Trub, Gregory R. Wagner, Kristin A. Anderson, Scott B. Crown, Guo-Fang Zhang, Olga R. Ilkayeva, Robert D. Stevens, Paul A. Grimsrud & Matthew D. Hirschey ...
The monoclonal antibody NC318, which targets Siglec-15, is currently undergoing clinical trials. This antibody offers hope to individuals who do not respond to PD-1/PD-L1 therapy [25]. The development of this antibody represents a potential breakthrough in the treatment of non-responders, ...